Optimized human cell products for research
and drug discovery

News & Events

ELRIG Drug Discovery 2017 Conference, 3-4th October 2017

Posted on

Visit DefiniGEN Stand iZ6 at ELRIG Drug Discovery 2017 Conference, 3-4th October 2017 ELRIG Drug Discovery conference will be held at the ACC in Liverpool from 3-4th October.  Please visit: https://elrig.org/portfolio/elrig-2017-events-programme/. DefiniGEN will be in the innovation zone at stand iZ6, which is located in ACC Hall 2. About DefiniGEN: DefiniGEN has world-leading expertise in […]

Join DefiniGEN at BioJapan 2017 Yokohama 11-13 October Booth C49

Posted on

Join DefiniGEN at BioJapan 2017 Yokohama 11-13 October Booth C49 DefiniGEN and Kishida Chemical will co-exhibit at Bio Japan 2017. DefiniGEN will launch its exciting product portfolio to the Japanese market. This includes: Human iPSC-Derived Pancreatic Beta Cells, wild-type Human iPSC-Derived hepatocytes, Human iPSC-Derived Alpha-one antitrypsin deficiency hepatocytes and recently developed Human iPS-Derived Intestinal Organoids. […]

DefiniGEN announces collaboration with Kishida Chemical to develop their iPSC-derived disease model business in the Japanese pharmaceutical market

Posted on

Cambridge UK – August, 2017 – DefiniGEN, the world leader in human iPSC differentiation and disease modelling using CRISPR gene-editing technology, announce the launch of their business partnership with Kishida Chemical who supply a wide variety of chemical compound libraries to Japanese pharmaceutical companies. DefiniGEN’s custom made disease models can be applied to various applications […]

DefiniGEN Licenses Cholangiocyte Stem Cell Technology from Cambridge Enterprise

Posted on

Cambridge, UK, 26 April 2017: DefiniGEN, a leading provider of stem cell products and services, today announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge. The technology will be used by DefiniGEN to develop optimised liver cell […]

DefiniGEN to attend: Advances in Cell-Based Screening for Drug Discovery 2016

Posted on

The Use of Genome Editing and iPS Directed Differentiation Systems to Model Human Liver and Pancreatic Disease in vitro   (by Dr. Marcus Yeo, Chief Executive Officer, DefiniGEN) Dr Marcus Yeo will be overviewing the use of CRISPR gene-editing in combination with induced Pluripotent (iPS) cell differentiation platforms to generate liver and pancreatic disease modelled […]